Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 11.0
(0.08%)
USD 11.0
(0.08%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 26.52 Billion USD | -2.02% |
| 2023 | 27.07 Billion USD | -4.22% |
| 2022 | 28.26 Billion USD | 0.71% |
| 2021 | 28.06 Billion USD | 7.63% |
| 2020 | 26.07 Billion USD | -7.39% |
| 2019 | 28.15 Billion USD | -8.55% |
| 2018 | 30.79 Billion USD | 5.59% |
| 2017 | 29.16 Billion USD | -2.38% |
| 2016 | 29.87 Billion USD | 11.23% |
| 2015 | 26.85 Billion USD | 24.53% |
| 2014 | 21.56 Billion USD | 2.13% |
| 2013 | 21.11 Billion USD | 3.82% |
| 2012 | 20.34 Billion USD | -0.73% |
| 2011 | 20.49 Billion USD | 7.99% |
| 2010 | 18.97 Billion USD | 7.74% |
| 2009 | 17.61 Billion USD | 5.83% |
| 2008 | 16.64 Billion USD | 9.18% |
| 2007 | 15.24 Billion USD | 15.76% |
| 2006 | 13.16 Billion USD | 11.71% |
| 2005 | 11.78 Billion USD | 15.59% |
| 2004 | 10.19 Billion USD | 15.89% |
| 2003 | 8.79 Billion USD | 15.7% |
| 2002 | 7.6 Billion USD | 15.68% |
| 2001 | 6.57 Billion USD | 10.1% |
| 2000 | 5.97 Billion USD | 17.77% |
| 1999 | 5.07 Billion USD | 16.4% |
| 1998 | 4.35 Billion USD | 13.29% |
| 1997 | 3.84 Billion USD | 12.73% |
| 1996 | 3.41 Billion USD | 12.04% |
| 1995 | 3.04 Billion USD | 11.16% |
| 1994 | 2.73 Billion USD | 12.22% |
| 1993 | 2.44 Billion USD | 11.47% |
| 1992 | 2.18 Billion USD | 10.12% |
| 1991 | 1.98 Billion USD | 12.87% |
| 1990 | 1.76 Billion USD | 10.41% |
| 1989 | 1.59 Billion USD | 8.24% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 7.04 Billion USD | 3.99% |
| 2024 Q1 | 6.77 Billion USD | 4.56% |
| 2024 Q3 | 6.45 Billion USD | -8.25% |
| 2024 Q4 | 6.25 Billion USD | -3.19% |
| 2023 Q2 | 7.05 Billion USD | 1.47% |
| 2023 Q4 | 6.47 Billion USD | -1.73% |
| 2023 Q1 | 6.95 Billion USD | 8.45% |
| 2023 FY | 27.07 Billion USD | -4.22% |
| 2023 Q3 | 6.58 Billion USD | -6.61% |
| 2022 Q4 | 6.41 Billion USD | -2.45% |
| 2022 Q1 | 7.57 Billion USD | 0.95% |
| 2022 FY | 28.26 Billion USD | 0.71% |
| 2022 Q3 | 6.57 Billion USD | -14.75% |
| 2022 Q2 | 7.7 Billion USD | 1.77% |
| 2021 FY | 28.06 Billion USD | 0.18% |
| 2021 Q1 | 6.63 Billion USD | 4.86% |
| 2021 Q2 | 6.78 Billion USD | 2.28% |
| 2021 Q3 | 7.15 Billion USD | 5.49% |
| 2021 Q4 | 7.5 Billion USD | 4.91% |
| 2020 Q4 | 6.32 Billion USD | 6.13% |
| 2020 FY | 28.01 Billion USD | -6.85% |
| 2020 Q1 | 6.77 Billion USD | -6.24% |
| 2020 Q2 | 7.01 Billion USD | 3.57% |
| 2020 Q3 | 5.95 Billion USD | -15.1% |
| 2019 Q3 | 7.45 Billion USD | -3.89% |
| 2019 FY | 30.07 Billion USD | -2.33% |
| 2019 Q2 | 7.75 Billion USD | 1.49% |
| 2019 Q1 | 7.64 Billion USD | 0.87% |
| 2019 Q4 | 7.22 Billion USD | -3.03% |
| 2018 Q2 | 8.09 Billion USD | 10.28% |
| 2018 FY | 30.79 Billion USD | 5.59% |
| 2018 Q1 | 7.34 Billion USD | 0.01% |
| 2018 Q3 | 7.78 Billion USD | -3.9% |
| 2018 Q4 | 7.57 Billion USD | -2.63% |
| 2017 Q4 | 7.34 Billion USD | 2.73% |
| 2017 Q2 | 7.56 Billion USD | 6.25% |
| 2017 Q1 | 7.11 Billion USD | -0.55% |
| 2017 Q3 | 7.14 Billion USD | -5.5% |
| 2017 FY | 29.16 Billion USD | -2.38% |
| 2016 Q1 | 7.41 Billion USD | 3.04% |
| 2016 Q2 | 7.86 Billion USD | 6.04% |
| 2016 Q4 | 7.15 Billion USD | -3.74% |
| 2016 FY | 29.87 Billion USD | 10.96% |
| 2016 Q3 | 7.43 Billion USD | -5.52% |
| 2015 FY | 26.92 Billion USD | 24.83% |
| 2015 Q4 | 7.2 Billion USD | -3.76% |
| 2015 Q3 | 7.48 Billion USD | 7.05% |
| 2015 Q2 | 6.98 Billion USD | 31.95% |
| 2015 Q1 | 5.29 Billion USD | -0.58% |
| 2014 FY | 21.56 Billion USD | 2.13% |
| 2014 Q1 | 5.15 Billion USD | -0.75% |
| 2014 Q2 | 5.65 Billion USD | 9.67% |
| 2014 Q4 | 5.32 Billion USD | -2.08% |
| 2014 Q3 | 5.44 Billion USD | -3.72% |
| 2013 FY | 21.11 Billion USD | 3.82% |
| 2013 Q3 | 5.22 Billion USD | -6.87% |
| 2013 Q1 | 5.09 Billion USD | 5.46% |
| 2013 Q2 | 5.6 Billion USD | 9.96% |
| 2013 Q4 | 5.19 Billion USD | -0.59% |
| 2012 Q4 | 4.83 Billion USD | -3.57% |
| 2012 Q1 | 5.1 Billion USD | 0.69% |
| 2012 Q3 | 5.01 Billion USD | -6.96% |
| 2012 Q2 | 5.38 Billion USD | 5.58% |
| 2012 FY | 20.34 Billion USD | -0.73% |
| 2011 Q2 | 5.32 Billion USD | 7.66% |
| 2011 FY | 20.49 Billion USD | 7.99% |
| 2011 Q4 | 5.06 Billion USD | -1.65% |
| 2011 Q3 | 5.15 Billion USD | -3.19% |
| 2011 Q1 | 4.94 Billion USD | 3.19% |
| 2010 Q4 | 4.79 Billion USD | 0.91% |
| 2010 FY | 18.97 Billion USD | 7.74% |
| 2010 Q3 | 4.74 Billion USD | -3.02% |
| 2010 Q2 | 4.89 Billion USD | 7.91% |
| 2010 Q1 | 4.53 Billion USD | 4.42% |
| 2009 Q2 | 4.65 Billion USD | 12.19% |
| 2009 Q3 | 4.45 Billion USD | -4.25% |
| 2009 Q4 | 4.34 Billion USD | -2.53% |
| 2009 FY | 17.61 Billion USD | 5.83% |
| 2009 Q1 | 4.15 Billion USD | 2.37% |
| 2008 Q1 | 3.9 Billion USD | 4.03% |
| 2008 FY | 16.64 Billion USD | 9.18% |
| 2008 Q3 | 4.23 Billion USD | -4.45% |
| 2008 Q4 | 4.05 Billion USD | -4.34% |
| 2008 Q2 | 4.43 Billion USD | 13.55% |
| 2007 Q4 | 3.75 Billion USD | -3.14% |
| 2007 Q2 | 4.03 Billion USD | 12.87% |
| 2007 FY | 15.24 Billion USD | 15.76% |
| 2007 Q3 | 3.87 Billion USD | -3.93% |
| 2007 Q1 | 3.57 Billion USD | 6.3% |
| 2006 Q3 | 3.34 Billion USD | -3.36% |
| 2006 FY | 13.16 Billion USD | 11.71% |
| 2006 Q1 | 3 Billion USD | 2.37% |
| 2006 Q2 | 3.45 Billion USD | 15.21% |
| 2006 Q4 | 3.36 Billion USD | 0.61% |
| 2005 Q2 | 3.13 Billion USD | 15.61% |
| 2005 Q1 | 2.7 Billion USD | 3.58% |
| 2005 Q3 | 3.01 Billion USD | -3.65% |
| 2005 Q4 | 2.93 Billion USD | -2.76% |
| 2005 FY | 11.78 Billion USD | 15.59% |
| 2004 FY | 10.19 Billion USD | 15.89% |
| 2004 Q2 | 2.7 Billion USD | 17.63% |
| 2004 Q3 | 2.57 Billion USD | -4.72% |
| 2004 Q4 | 2.61 Billion USD | 1.42% |
| 2004 Q1 | 2.3 Billion USD | 3.36% |
| 2003 Q1 | 1.99 Billion USD | 3.08% |
| 2003 Q4 | 2.22 Billion USD | -0.21% |
| 2003 Q3 | 2.23 Billion USD | -5.03% |
| 2003 Q2 | 2.34 Billion USD | 17.66% |
| 2003 FY | 8.79 Billion USD | 15.7% |
| 2002 Q3 | 1.93 Billion USD | -4.75% |
| 2002 Q4 | 1.93 Billion USD | -0.06% |
| 2002 Q2 | 2.03 Billion USD | 19.79% |
| 2002 Q1 | 1.69 Billion USD | 2.06% |
| 2002 FY | 7.6 Billion USD | 15.68% |
| 2001 Q4 | 1.66 Billion USD | 0.73% |
| 2001 FY | 6.57 Billion USD | 10.1% |
| 2001 Q3 | 1.65 Billion USD | -6.73% |
| 2001 Q2 | 1.77 Billion USD | 19.0% |
| 2001 Q1 | 1.48 Billion USD | -12.69% |
| 2000 Q4 | 1.7 Billion USD | 17.46% |
| 2000 Q2 | 1.54 Billion USD | 21.33% |
| 2000 Q3 | 1.45 Billion USD | -5.99% |
| 2000 Q1 | 1.27 Billion USD | -12.64% |
| 2000 FY | 5.97 Billion USD | 17.77% |
| 1999 Q4 | 1.45 Billion USD | 17.38% |
| 1999 Q1 | 1.07 Billion USD | -12.82% |
| 1999 FY | 5.07 Billion USD | 16.4% |
| 1999 Q2 | 1.29 Billion USD | 20.91% |
| 1999 Q3 | 1.24 Billion USD | -4.46% |
| 1998 Q4 | 1.23 Billion USD | 17.67% |
| 1998 Q2 | 1.13 Billion USD | 20.02% |
| 1998 Q3 | 1.04 Billion USD | -7.59% |
| 1998 Q1 | 944 Million USD | -12.29% |
| 1998 FY | 4.35 Billion USD | 13.29% |
| 1997 Q2 | 1 Billion USD | 21.22% |
| 1997 Q4 | 1.07 Billion USD | 15.4% |
| 1997 FY | 3.84 Billion USD | 12.73% |
| 1997 Q1 | 830 Million USD | -13.49% |
| 1997 Q3 | 932.7 Million USD | -7.3% |
| 1996 Q3 | 823.2 Million USD | -7.43% |
| 1996 FY | 3.41 Billion USD | 12.04% |
| 1996 Q1 | 739 Million USD | -13.31% |
| 1996 Q2 | 889.3 Million USD | 20.34% |
| 1996 Q4 | 959.4 Million USD | 16.55% |
| 1995 Q1 | 664.8 Million USD | -14.76% |
| 1995 Q4 | 852.5 Million USD | 16.91% |
| 1995 Q3 | 729.2 Million USD | -8.61% |
| 1995 Q2 | 797.9 Million USD | 20.02% |
| 1995 FY | 3.04 Billion USD | 11.16% |
| 1994 FY | 2.73 Billion USD | 12.22% |
| 1994 Q1 | 589.8 Million USD | -14.9% |
| 1994 Q4 | 779.9 Million USD | 18.87% |
| 1994 Q3 | 656.1 Million USD | -7.97% |
| 1994 Q2 | 712.9 Million USD | 20.87% |
| 1993 Q3 | 581.8 Million USD | -8.84% |
| 1993 Q4 | 693.1 Million USD | 19.13% |
| 1993 Q2 | 638.2 Million USD | 21.01% |
| 1993 Q1 | 527.4 Million USD | -14.83% |
| 1993 FY | 2.44 Billion USD | 11.47% |
| 1992 Q1 | 471.4 Million USD | -15.96% |
| 1992 Q4 | 619.2 Million USD | 17.81% |
| 1992 FY | 2.18 Billion USD | 10.12% |
| 1992 Q2 | 573.2 Million USD | 21.6% |
| 1992 Q3 | 525.6 Million USD | -8.3% |
| 1991 Q4 | 560.9 Million USD | 16.64% |
| 1991 Q1 | 428.6 Million USD | -3.69% |
| 1991 Q2 | 517.7 Million USD | 20.79% |
| 1991 FY | 1.98 Billion USD | 12.87% |
| 1991 Q3 | 480.9 Million USD | -7.11% |
| 1990 Q3 | 440.1 Million USD | -7.66% |
| 1990 Q1 | 398.8 Million USD | -70.26% |
| 1990 FY | 1.76 Billion USD | 10.41% |
| 1990 Q2 | 476.6 Million USD | 19.51% |
| 1990 Q4 | 445 Million USD | 1.11% |
| 1989 FY | 1.59 Billion USD | 8.24% |
| 1989 Q4 | 1.34 Billion USD | -0.72% |
| 1989 Q3 | 1.35 Billion USD | -8.53% |
| 1989 Q1 | 1.21 Billion USD | 0.82% |
| 1989 Q2 | 1.47 Billion USD | 21.87% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Imunon, Inc. | -720 Thousand USD | 3683963.307% |
| Homology Medicines, Inc. | -7.22 Million USD | 367011.053% |
| uniQure N.V. | 2.21 Million USD | -1197371.783% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -8782681.457% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 31225.61% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -153049.72% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -7226.465% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 8474221.406% |
| bluebird bio, Inc. | -4.03 Million USD | 658263.772% |
| Blueprint Medicines Corporation | 236.58 Million USD | -11111.24% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -179188.901% |
| Adicet Bio, Inc. | -6.09 Million USD | 435062.283% |
| Dynavax Technologies Corporation | 182.11 Million USD | -14464.264% |
| Editas Medicine, Inc. | -99.52 Million USD | 26749.787% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -36200.929% |
| Geron Corporation | -123.5 Million USD | 21576.401% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -264030.651% |
| Illumina, Inc. | 2.74 Billion USD | -866.618% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 277373.678% |
| IQVIA Holdings Inc. | 5.23 Billion USD | -406.28% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -1122.827% |
| Myriad Genetics, Inc. | 476.4 Million USD | -5467.59% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -1335.748% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -2326.731% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -4964.326% |
| Verastem, Inc. | -62 Thousand USD | 42780745.161% |
| Waters Corporation | 1.76 Billion USD | -1406.025% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | -208.168% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | -74.225% |
| Biogen Inc. | 7.3 Billion USD | -263.233% |
| Nektar Therapeutics | 53.47 Million USD | -49497.966% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 9083661.644% |
| Perrigo Company plc | 1.68 Billion USD | -1478.434% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 134746.429% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 85201.031% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -1292.795% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 58619.581% |
| Evolus, Inc. | 140.52 Million USD | -18774.799% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | -134.697% |
| FibroGen, Inc. | 128.9 Million USD | -20476.553% |
| Agilent Technologies, Inc. | 3.46 Billion USD | -665.483% |
| OPKO Health, Inc. | 318.12 Million USD | -8237.551% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -1647.43% |
| Exelixis, Inc. | 1.75 Billion USD | -1409.051% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 6751.053% |
| Zoetis Inc. | 5.83 Billion USD | -354.645% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -10746.709% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 8753895.38% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -3307.004% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -5473.51% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -4064.599% |
| Insmed Incorporated | 239.63 Million USD | -10968.5% |
| TG Therapeutics, Inc. | 219.1 Million USD | -12005.446% |
| Incyte Corporation | 3.44 Billion USD | -670.901% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -7612.707% |